Clinical Trials Browser

Withdrawn × Myeloid × 1 year × Clear all

Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Mastocytosis, Myositis, Sjogren's Syndrome, Vasculitis, Arthritis, Psoriatic, Antiphospholipid Syndrome, Spondylarthritis, Rare Diseases, Scleroderma, Diffuse

NCT04953312 2026-03-12

CALPRO

Phase NA Withdrawn

MyeloidOther hematologic neoplasm

COVID-19, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05170828 2026-02-24

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06284460 2026-02-13

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Withdrawn

Classical hematologyMyeloid

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders

NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Clinical Trials

EGR2

CALPRO

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor